JPRN-UMIN000008793
Completed
Phase 2
Phase II study of remission induction therapy with bendamustine and rituximab combination (BR) therapy followed by consolidation therapy with 90Y-labeled iburitumomab tiuxetan for relapsed follicular lymphoma.(BRiZ2012 protocol) - Phase II study of remission induction therapy with BR therapy followed by consolidation therapy with 90Y-labeled iburitumomab tiuxetan for relapsed follicular lymphoma.
Society of Lymphoma Treatment in Japan (SoLTJ)0 sites28 target enrollmentSeptember 3, 2012
Conditionsfollicular lymphoma
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- follicular lymphoma
- Sponsor
- Society of Lymphoma Treatment in Japan (SoLTJ)
- Enrollment
- 28
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Histologically confirmed CD20 negative lymphoma by biopsy at the time of diagnosis or relapse. Having active double or multiple cancer. Having infectious disease with poor control (including active tuberculosis ). Having the central nervous system infiltration of the lymphoma. Intolerant to the drugs using in this study. If any of HIV antibody, HBs antigen or HCV antibody positivity. Pregnant (including possibility), nursing women. Had received bendamustine administration previously.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
TOP-ILD studyProgressive pulmonary fibrosisinterstitial pneumonia, IP, PPFJPRN-jRCTs071230004Okamoto Isamu32
Not yet recruiting
Not Applicable
Prediction of therapeutic efficacy of ulcerative colitis based on gene expression in the colonic mucosa.ulcerative colitisJPRN-UMIN000050517Kyoto Prefectural University of Medicine100
Completed
Phase 2
A phase II study of the remission induction and maintenance therapy by rituximab for rituximab naive low grade B cell lymphoma.low grade B cell lymphomaJPRN-UMIN000001191Clinical Hematology Study Group of National Hospital Organization(CHSG-NHO)42
Active, not recruiting
Not Applicable
Phase II study of first line treatment of chronic graft versus host disease with the association of ciclosporine, corticosteroids and Rituximab - R-GVHDChronic graft versus host diseaseMedDRA version: 12.1Level: LLTClassification code 10066261Term: Chronic graft versus host diseaseEUCTR2009-016898-14-FRCHU de Nantes
Active, not recruiting
Not Applicable
A phase II study for the treatment of patients with splenic marginal lymphoma with the combination of Cyclophosfamide, Vincristine, Liposomal Doxorubicin, Predinisone and RituximabTreatment of patients with newly diagnosed splenic marginal non Hodgkin lymphomaMedDRA version: 9.1Level: LLTClassification code 10062113Term: Splenic marginal zone lymphomaEUCTR2005-000693-45-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI